{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.315","upperLimit":"0.639","value":"0.475"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Single arm interventional study: all subjects receive Doxil, Rituximab, Cyclophosphamide, Vincristine and Prednisone (DR-COP) regimen.","id":"OG000","title":"DR-COP"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation","title":"Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .","type":"PRIMARY","unitOfMeasure":"proportion of patients"}